11/04/2025
Our CEO, DG Kim was recently interviewed by Korea Biomedical Review. The article covers HLB and Elevar’s plans to resubmit their liver cancer drug candidate to the FDA by January for a potential U.S. launch.
You can read the full interview here:
Elevar Therapeutics plans to return its liver cancer regimen to the U.S. Food and Drug Administration (FDA) as early as December, aiming for a 2026 decision that could pave the way for a direct U.S...